Related Experiment Videos
[A clinical study of cefotiam in pediatric field (author's transl)]
The Japanese Journal of Antibiotics
|May 1, 1981
Insights
Cefotiam, a new cephalosporin antibiotic, showed a 92% clinical response rate in pediatric infections. This effective antibiotic was well-tolerated, with no significant side effects observed in treated children.
Area of Science:
- Pharmacology
- Microbiology
- Pediatrics
Context:
- Pediatric infections pose significant health challenges.
- Novel antibiotics are crucial for combating resistant bacterial strains.
- Cephalosporins are a vital class of antibiotics in clinical practice.
Purpose:
- To evaluate the efficacy and safety of cefotiam in treating pediatric infections.
- To assess the antimicrobial spectrum of cefotiam against common pediatric pathogens.
- To determine the clinical outcomes and tolerability of cefotiam in young patients.
Summary:
- Cefotiam, a novel semisynthetic cephalosporin, was administered to 12 pediatric patients with various infections.
- A high clinical response rate of 92% was observed.
- The antibiotic demonstrated broad-spectrum activity against Gram-positive and Gram-negative bacteria.
- No significant adverse effects or laboratory abnormalities were reported during the treatment period.
Impact:
- Cefotiam presents a promising therapeutic option for pediatric bacterial infections.
- The favorable safety profile supports its potential use in a pediatric population.
- Further research may establish cefotiam as a key antibiotic in pediatric infectious disease management.
Abstract:
Cefotiam is a new semisynthetic cephalosporin antibiotic. The treatment with this drug was carried out in 12 cases of pediatric infection. The clinical response was observed in 92% of the cases. Cefotiam was found to be active against a variety of Gram-positive and Gram-negative bacteria. Neither marked side effects nor laboratory abnormalities were found with this treatment.